Prognostic Disclosure in Metastatic Breast Cancer: Protocol for a Scoping Review

BackgroundPrognostic disclosure enables shared decision-making by keeping patients informed about their health and involved in treatment-related choices. In metastatic cancer, patients who understand their prognosis are better placed to evaluate their health situation, have m...

Full description

Saved in:
Bibliographic Details
Main Authors: Linda Battistuzzi, Irene Giannubilo, Claudia Bighin
Format: Article
Language:English
Published: JMIR Publications 2025-04-01
Series:JMIR Research Protocols
Online Access:https://www.researchprotocols.org/2025/1/e57256
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849311405151354880
author Linda Battistuzzi
Irene Giannubilo
Claudia Bighin
author_facet Linda Battistuzzi
Irene Giannubilo
Claudia Bighin
author_sort Linda Battistuzzi
collection DOAJ
description BackgroundPrognostic disclosure enables shared decision-making by keeping patients informed about their health and involved in treatment-related choices. In metastatic cancer, patients who understand their prognosis are better placed to evaluate their health situation, have more realistic expectations about treatment, and better end-of-life (EoL) care. However, many oncologists feel uncomfortable discussing prognoses with their patients, as they worry about causing psychological distress and diminishing hope. Other barriers to prognostic disclosure are associated with the inherent uncertainty of prognostication, which is especially prominent in metastatic breast cancer (mBC), as are a lack of timely discussions about EoL care and poor quality of care at EoL. Despite this background, a preliminary literature search has shown that, to date, knowledge about prognostic disclosure in mBC has not been systematically mapped. ObjectiveThe overall aim of this scoping review will be to comprehensively explore the existing literature pertaining to prognostic disclosure in mBC. MethodsThis scoping review will follow Arksey and O’Malley’s expanded framework. We will systematically search electronic databases for peer-reviewed, published journal articles to identify appropriate studies. First, 2 members of the research team will independently review titles and abstracts. Then, they will review full texts to establish whether articles meet inclusion criteria. A data chart for collecting and sorting information will be developed. Results will be reported following the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews) guidelines and summarized quantitatively and qualitatively. ResultsWe expect to present the results in a scoping review in 2025. ConclusionsTo our knowledge, this scoping review will be the first systematic effort aimed at mapping existing literature on prognostic disclosure in mBC, in which rapidly developing therapeutic approaches and changing disease trajectories generate new uncertainties and place new communicative demands on oncologists. The insights gained from this scoping review will inform the development of an interview schedule with oncologists, oncology residents, oncology nurses, and patients with mBC to explore their experiences, views, and perceptions about prognostic disclosure. International Registered Report Identifier (IRRID)PRR1-10.2196/57256
format Article
id doaj-art-b4fc17be0d3b410fb9d02e71a2816186
institution Kabale University
issn 1929-0748
language English
publishDate 2025-04-01
publisher JMIR Publications
record_format Article
series JMIR Research Protocols
spelling doaj-art-b4fc17be0d3b410fb9d02e71a28161862025-08-20T03:53:23ZengJMIR PublicationsJMIR Research Protocols1929-07482025-04-0114e5725610.2196/57256Prognostic Disclosure in Metastatic Breast Cancer: Protocol for a Scoping ReviewLinda Battistuzzihttps://orcid.org/0000-0003-2340-3059Irene Giannubilohttps://orcid.org/0009-0009-2377-2699Claudia Bighinhttps://orcid.org/0000-0001-9956-0216 BackgroundPrognostic disclosure enables shared decision-making by keeping patients informed about their health and involved in treatment-related choices. In metastatic cancer, patients who understand their prognosis are better placed to evaluate their health situation, have more realistic expectations about treatment, and better end-of-life (EoL) care. However, many oncologists feel uncomfortable discussing prognoses with their patients, as they worry about causing psychological distress and diminishing hope. Other barriers to prognostic disclosure are associated with the inherent uncertainty of prognostication, which is especially prominent in metastatic breast cancer (mBC), as are a lack of timely discussions about EoL care and poor quality of care at EoL. Despite this background, a preliminary literature search has shown that, to date, knowledge about prognostic disclosure in mBC has not been systematically mapped. ObjectiveThe overall aim of this scoping review will be to comprehensively explore the existing literature pertaining to prognostic disclosure in mBC. MethodsThis scoping review will follow Arksey and O’Malley’s expanded framework. We will systematically search electronic databases for peer-reviewed, published journal articles to identify appropriate studies. First, 2 members of the research team will independently review titles and abstracts. Then, they will review full texts to establish whether articles meet inclusion criteria. A data chart for collecting and sorting information will be developed. Results will be reported following the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews) guidelines and summarized quantitatively and qualitatively. ResultsWe expect to present the results in a scoping review in 2025. ConclusionsTo our knowledge, this scoping review will be the first systematic effort aimed at mapping existing literature on prognostic disclosure in mBC, in which rapidly developing therapeutic approaches and changing disease trajectories generate new uncertainties and place new communicative demands on oncologists. The insights gained from this scoping review will inform the development of an interview schedule with oncologists, oncology residents, oncology nurses, and patients with mBC to explore their experiences, views, and perceptions about prognostic disclosure. International Registered Report Identifier (IRRID)PRR1-10.2196/57256https://www.researchprotocols.org/2025/1/e57256
spellingShingle Linda Battistuzzi
Irene Giannubilo
Claudia Bighin
Prognostic Disclosure in Metastatic Breast Cancer: Protocol for a Scoping Review
JMIR Research Protocols
title Prognostic Disclosure in Metastatic Breast Cancer: Protocol for a Scoping Review
title_full Prognostic Disclosure in Metastatic Breast Cancer: Protocol for a Scoping Review
title_fullStr Prognostic Disclosure in Metastatic Breast Cancer: Protocol for a Scoping Review
title_full_unstemmed Prognostic Disclosure in Metastatic Breast Cancer: Protocol for a Scoping Review
title_short Prognostic Disclosure in Metastatic Breast Cancer: Protocol for a Scoping Review
title_sort prognostic disclosure in metastatic breast cancer protocol for a scoping review
url https://www.researchprotocols.org/2025/1/e57256
work_keys_str_mv AT lindabattistuzzi prognosticdisclosureinmetastaticbreastcancerprotocolforascopingreview
AT irenegiannubilo prognosticdisclosureinmetastaticbreastcancerprotocolforascopingreview
AT claudiabighin prognosticdisclosureinmetastaticbreastcancerprotocolforascopingreview